Naomi Pearce most recently ran her own consultancy, Pearce IP Strategy, with a specialisation in global patent strategies and pharmaceuticals.
According to a release from K&L Gates, Ms Pearce has built and led the global IP teams for numerous global companies, managing the legal issues relating to the development and sale of pharmaceuticals, biopharmaceuticals and medical devices.
Her recent work includes the development and execution of strategies supporting “the launch of the world’s first biosimilar monoclonal antibody product; two of the EU’s first biosimilar products; and Australia’s first biosimilar product”, according to the statement.
Earlier this week, K&L Gates announced the appointment of corporate partner Jeremy Prentice, formerly of Holding Redlich.
Like this story? Read more:
In September, special counsel Leonard McCarthy came to K&L Gates’ restructuring and insolvency team from Henry Davis York.